Review on Starter Pellets: Inert and Functional Cores

Introduction to Starter Pellet Technologies

Review on starter pellets: inert and functional cores examines the core particles used in multiparticulate drug delivery systems. Starter pellets provide a foundation for drug layering and controlled release. Unlike single-unit dosage forms, multiparticulates offer advantages such as more uniform gastrointestinal transit, reduced risk of dose dumping, and improved patient-centric design. These cores are essential in both immediate and modified or extended release delivery systems.
Starter pellets can be broadly categorized as inert or functional. Inert cores serve primarily as neutral substrates for layering the active pharmaceutical ingredient (API). In contrast, functional cores include specific excipients that interact with the dissolution environment to support targeted release characteristics.
The following information refer to a publication by N. Kállai-Szabó et al. [1].

Types of Starter Pellet Cores

Inert Pellet Cores

Inert pellet cores consist solely of excipients approved in pharmacopeias. These cores include sugar spheres, microcrystalline cellulose (MCC), isomalt, and calcium phosphate salts. They do not directly influence drug release but provide necessary mechanical support and uniform surface for API deposition.
Inert cores vary in solubility and mechanical properties. Water-soluble cores such as sugar and isomalt can dissolve during dissolution, which may accelerate drug release. Conversely, insoluble cores like MCC and calcium phosphate remain intact and may retard release.

Functional Pellet Cores

Functional pellet cores include excipients that actively modulate the dissolution environment. One such category involves tartaric acid cores. These tartaric acid cores or pellets can be purchased from IPC Process Center GmbH, Germany (TAP®) These cores dissolve rapidly and can alter micro environmental pH within the pellet. This attribute benefits the dissolution of weakly basic drugs with poor solubility at near-neutral pH by maintaining a localized acidic environment around the API layer.
Functional cores also support modified release strategies. For example, formulating weakly basic drugs on pH-modifying cores combined with appropriate polymer coatings can improve dissolution where pH normally limits solubility.

Layering and Coating Techniques

Drug Layering Methods

Formulators apply APIs to starter pellet cores using one of three primary techniques: solution layering, suspension layering, and dry powder layering. Solution and suspension techniques involve dissolving or suspending the API in a liquid binder and spraying it onto the core. These methods yield smoother surfaces but may require higher solvent volumes and longer processing times.
Dry powder layering minimizes liquid exposure, benefiting moisture-sensitive APIs and reducing process times. However, it produces a rougher pellet surface. All layering approaches commonly use fluid bed coaters or drum coaters to ensure consistent application of materials.

Polymer Coatings

After drug layering, formulators typically add a polymer film coat. This coat may mask taste, protect the API from environmental factors like moisture, or precisely control drug release. Film thickness and uniformity significantly influence performance and stability.
In some cases, a seal coat is necessary between the API and the functional core to prevent direct interaction that could compromise stability or prematurely alter micro environmental conditions. Seal coats often dissolve rapidly to maintain core function until the final release target region is reached.

Core Characteristics and Quality Attributes

Pharmaceutical scientists evaluate starter pellets based on characteristics such as particle size, size distribution, shape, surface roughness, and mechanical strength. These quality attributes influence coating uniformity, drug loadability, and dissolution behavior.
Starter cores are available in a wide range of size fractions, typically between 200 µm and 2 mm, to support different formulation goals. Smaller pellets allow higher drug loading and smoother taste masking, while larger cores may be preferable for controlled release applications.

Dissolution Mechanisms and Drug Release

The drug release from pellet systems depends on the core type and the coating strategy. Water-soluble cores may contribute to drug release by dissolving and generating osmotic forces that draw dissolution medium inward. Insoluble cores maintain structural integrity, often delaying release until polymer coatings permit medium penetration.
Functional cores such as tartaric acid spheres influence the micro environmental pH, which can enhance the dissolution of pH-sensitive APIs in media where they otherwise show limited solubility. This pH modification occurs concurrently with coating dissolution and medium ingress, making the design of both core and coating crucial to performance.

Pharmaceutical Applications and Patient-Centric Design

Multiparticulate systems built from starter cores serve a wide range of pharmaceutical needs. They support dose tailoring, improved swallowability, taste masking, and once-daily dosing. These benefits make them particularly useful in pediatric and geriatric populations.
In pediatric formulations, smaller pellet sizes improve acceptability and ease of administration. For older patients with dysphagia, multiparticulates in gel or carrier solutions enhance therapy adherence.

Future Perspectives

Starter pellet technology continues to evolve. Advances in manufacturing such as 3D printing may yield new core structures with tailored porosity and morphology. In addition, combining inert cores with novel functional excipients may expand the capabilities of multiparticulate drug delivery systems.

Conclusions

Starter pellets remain a cornerstone in multiparticulate formulation design. Both inert and functional cores provide versatile platforms for drug layering and controlled release. The selection of appropriate core material, size, and coating architecture directly influences manufacturing efficiency and final product performance. Knowledge of core properties and release mechanisms enables optimized design tailored to API characteristics and therapeutic goals.

References

[1] N. Kállai-Szabó et al., Pharmaceutics, 2022, 14(6):1299. doi: 10.3390/pharmaceutics14061299